ReviewTherapeutic advances in gastroenterology2025

Microbiota-targeted strategies in IBD: therapeutic promise of 2'-fucosyllactose and beyond.

Nicholas Fanous et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.